25693-41-8

Basic information

• Product Name: ETHYL 4-HYDROXY-2-MORPHOLINOPYRIMIDINE-5-CARBOXYLATE
• Synonyms: ETHYL 4-HYDROXY-2-MORPHOLINOPYRIMIDINE-5-CARBOXYLATE
• CAS NO: 25693-41-8
• Molecular Formula: C₁₁H₁₅N₃O₄
• Molecular Weight: 253.25
• Mol File: 25693-41-8.mol

Chemical Properties

• Melting Point: 168-170 °C(Solv: ethanol (64-17-5))
• Appearance: /
• Density: 1.40±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 9.10±0.50(Predicted)
• CAS DataBase Reference: ETHYL 4-HYDROXY-2-MORPHOLINOPYRIMIDINE-5-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 4-HYDROXY-2-MORPHOLINOPYRIMIDINE-5-CARBOXYLATE(25693-41-8)
• EPA Substance Registry System: ETHYL 4-HYDROXY-2-MORPHOLINOPYRIMIDINE-5-CARBOXYLATE(25693-41-8)

Safety Data

• Hazardous Substances Data: 25693-41-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
ETHYL 4-HYDROXY-2-MORPHOLINOPYRIMIDINE-5-CARBOXYLATE is used as a key building block for the development of new pharmaceuticals, leveraging its chemical structure to create compounds with therapeutic potential.
Used in Agrochemical Development:
In the agrochemical industry, ETHYL 4-HYDROXY-2-MORPHOLINOPYRIMIDINE-5-CARBOXYLATE is utilized as a component in the synthesis of various agrochemicals, contributing to the creation of effective products for crop protection and enhancement.
Used in Antimicrobial Applications:
ETHYL 4-HYDROXY-2-MORPHOLINOPYRIMIDINE-5-CARBOXYLATE is employed as an antimicrobial agent for its antifungal and antibacterial properties, serving as a valuable asset in the development of treatments for microbial infections.
Used in Neurological Disorder Treatment:
ETHYL 4-HYDROXY-2-MORPHOLINOPYRIMIDINE-5-CARBOXYLATE is being studied for its potential role in the treatment of neurological disorders, indicating its use as a therapeutic agent in the medical field for conditions that affect the nervous system.

Upstream product

• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 157415-17-3 Morpholine-4-carboxamidine; hydrobromide 
• 157415-17-3 morpholine-4-carboxamidine hydrobromide 
• 17238-66-3 morpholine-4-carboxamidine 
• 110-91-8 morpholine 
• 53554-29-3 ethyl 3,4-dihydro-2-methylthio-4-oxopyrimidine-5-carboxylate 
• 851758-36-6 2-morpholin-4-yl-4-(4-nitro-benzyloxy)-pyrimidine-5-carboxylic acid ethyl ester 
• 5638-78-8 morpholinoformamidine hydrochloride 

Downstream Products

• 34750-23-7 ethyl 4-chloro-2-(morpholin-1-yl)pyrimidine-5-carboxylate 
• 1353875-60-1 ethyl 4-((4-methoxybenzyl)amino)-2-(4-morpholinyl)-5-pyrimidine-carboxylate 

Relevant articles and documents

Microwave-assisted synthesis and antibacterial evaluation of new derivatives of 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one

Synthesis of new 1,2-dihydro-3H-pyrazolo[3,4-d] pyrimidin-3-ones 4-6 starting with ethyl 4-hydroxy-2-methylthio-pyrimidine-5-carboxylate (1) under classical heating and microwave-induced conditions is reported. The antibacterial activities of the synthesized compounds were evaluated using chloramphenicol and streptomycin as reference drugs.

NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS

Substituted bicyclic heteroaryls of the following formulae and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory o

Optimisation of pharmacokinetic properties in a neutral series of 11β-HSD1 inhibitors

11β-HSD1 is increasingly seen as an attractive target for the treatment of type II diabetes and other elements of the metabolic syndrome. In this program of work we describe how a series of neutral 2-thioalkyl-pyridine 11β-HSD1 inhibitors were optimized in terms of their pharmacokinetic properties to give compounds with excellent bioavailability in both rat and dog through a core change to pyrimidine. A potential reactive metabolite issue with 4-thioalkyl-pyrimidines was circumvented by a switch from sulfur to carbon substitution.

SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281

A compound of formula (I): and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11betaHSD1, processes for making them and pharmaceutical compositions comprising them are also described.

PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE -3-KINASES (PI3K)

The present invention provides pyrimidines of Formula (I): wherein R4, R6, and Y have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment